The risk for MDD is greatest in the first month after diagnosis and the absolute risk remains elevated even 20 years later, making early detection and treatment imperative.
The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.